Identifying genetic modulators of statin response using subject-derived lymphoblastoid cell lines

Area of Science:

• Pharmacogenomics
• Cardiovascular Disease Research
• Biomarker Discovery

Background:

• Statins effectively lower LDL cholesterol and reduce cardiovascular disease risk.
• Individual responses to statins, including efficacy and adverse effects (myopathy, diabetes), vary significantly.
• Predictive biomarkers are needed to personalize statin therapy and improve patient outcomes.

Purpose of the Study:

• To review the utility of lymphoblastoid cell lines in statin pharmacogenomic studies.
• To explore methods for identifying genetic markers associated with statin response variability.

Main Methods:

• Utilizing subject-derived lymphoblastoid cell lines for genetic analysis.
• Employing various approaches to discover novel genetic markers.
• Investigating interindividual variations in response to statin treatment.

Main Results:

• Lymphoblastoid cell lines provide a valuable model for pharmacogenomic research.
• Multiple genetic markers can influence statin efficacy and tolerability.
• The review highlights strategies for identifying these predictive markers.

Conclusions:

• Personalized statin therapy can be advanced through pharmacogenomic biomarker discovery.
• Lymphoblastoid cell lines are instrumental in understanding genetic influences on statin response.
• Identifying genetic predictors will optimize statin use and minimize adverse events.